PTG-CARCIK-CD19

DRUG3 trials

Sponsors

Fondazione Tettamanti, Fondazione Matilde Tettamanti Menotti De Marchi Onlus

Conditions

Acute Lymphoblastic LeukemiaB cell precursor Acute Lymphoblastic LeukemiaB-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Phase 1

Phase I/II Trial to Determine Persistence, Safety and Clinical Activity of Allogeneic CIK Cells Transduced with a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) in Adult and Pediatric Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia

RecruitingCTIS2023-505511-20-00

Fondazione TettamantiB-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Start: 2024-01-29Target: 38Updated: 2023-11-23

Phase 2

Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL

Fondazione Matilde Tettamanti Menotti De Marchi OnlusAcute Lymphoblastic Leukemia

Start: 2021-12-01End: 2025-03-31Target: 35Updated: 2023-05-06

Measurable residual disease driven strategy for one or two infusions of nonviral, transposon-manipulated CARCIK CD19 cells. A Phase II study in pediatric and adult patients with relapsed/refractory B cell precursor ALL (BCP-ALL).

Active, not recruitingCTIS2024-519394-19-00

Fondazione TettamantiB cell precursor Acute Lymphoblastic Leukemia

Start: 2021-09-22Target: 33Updated: 2025-07-31

Related Papers

Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability.

2025-05-192 citations

CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

Blood2024-11-05